Trial · NCT00462644
Evaluation of Etomidate on Adrenal Function in Trauma Patients
NCT00462644, Not applicable, Completed, University of Tennessee; results first posted 2009-11-11
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation of Etomidate on Adrenal Function in Trauma Patients. Trials, record NCT00462644. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00462644
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of Etomidate on Adrenal Function in Trauma Patients
- NCT number
- NCT00462644
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 30 participants, actual
- Lead sponsor
- University of Tennessee
- Conditions
- Adrenal Insufficiency
- Interventions
- RSI sedation with etomidate/succinylcholine, RSI sedation with fentanyl/midazolam/succinylcholine
- First posted
- 2007-04-19
- Last updated
- 2010-02-23
- Results first posted
- 2009-11-11
- Limitations and caveats
- Small trial most likely underpowered; large number of exclusions; other limitations discussed in published paper (PMID: 18784570).
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cortisol Levels Pre and Post Rapid Sequence Induction and Cortisol Stimulation Test | pre RSI, 4-6 hours post RSI, and again 60 mins later following ACTH stimulation test | |
| Primary | Postintubation Cortisol (Baseline Cortisol Level) | postintubation (baseline cortisol level) | cortisol level after randomization and rapid sequence induction |
| Primary | Change in Baseline Cortisol | 4-6hr after RSI | change from baseline cortisol (drawn prior to RSI) to 2nd cortisol level (4-6hrs after RSI, but before stim test) |
| Primary | Cortisol Level 60 Minutes After Cortisol Stimulating Test (CST) | 60 minutes after administration of cotrosyn | |
| Secondary | Hospital Length of Stay | time to hospital discharge in days | days from admission to hospital discharge |
| Secondary | Intensive Care Unit (ICU) Length of Stay | time from hospital admission to transfer out of ICU to floor bed | ICU length of stay in days |
| Secondary | Ventilator Days | time from intubation to extubation | |
| Secondary | Number of Deaths | death in hospital | deaths |
Source ClinicalTrials.gov
Outcomes8
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cortisol Levels Pre and Post Rapid Sequence Induction and Cortisol Stimulation Test | pre RSI, 4-6 hours post RSI, and again 60 mins later following ACTH stimulation test | |||
| SECONDARY | Hospital Length of Stay | time to hospital discharge in days | days | MEAN | |
| SECONDARY | Intensive Care Unit (ICU) Length of Stay | time from hospital admission to transfer out of ICU to floor bed | days | MEAN | |
| SECONDARY | Ventilator Days | time from intubation to extubation | days | MEAN | |
| PRIMARY | Postintubation Cortisol (Baseline Cortisol Level) | postintubation (baseline cortisol level) | micrograms/dL | MEAN | |
| PRIMARY | Change in Baseline Cortisol | 4-6hr after RSI | micrograms/dL | MEAN | |
| PRIMARY | Cortisol Level 60 Minutes After Cortisol Stimulating Test (CST) | 60 minutes after administration of cotrosyn | micrograms/dL | MEAN | |
| SECONDARY | Number of Deaths | death in hospital | participants | NUMBER |
Source ClinicalTrials.gov
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Hospital Length of Stay | Etomidate | 13.9 | Standard Deviation 9.5 | days | |
| Hospital Length of Stay | Fentanyl-Midazolam | 6.4 | Standard Deviation 4.4 | days | |
| Intensive Care Unit (ICU) Length of Stay | Etomidate | 8.1 | Standard Deviation 7.2 | days | |
| Intensive Care Unit (ICU) Length of Stay | Fentanyl-Midazolam | 3.0 | Standard Deviation 2.4 | days | |
| Ventilator Days | Etomidate | 6.3 | Standard Deviation 6.5 | days | |
| Ventilator Days | Fentanyl-Midazolam | 1.5 | Standard Deviation 0.8 | days | |
| Postintubation Cortisol (Baseline Cortisol Level) | Etomidate | 18.2 | Standard Deviation 8.4 | micrograms/dL | |
| Postintubation Cortisol (Baseline Cortisol Level) | Fentanyl-Midazolam | 27.9 | Standard Deviation 13.4 | micrograms/dL | |
| Change in Baseline Cortisol | Etomidate | -12.8 | Standard Deviation 9.6 | micrograms/dL | |
| Change in Baseline Cortisol | Fentanyl-Midazolam | 1.1 | Standard Deviation 7.6 | micrograms/dL |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Etomidate | 18 | |
| Overall Study | STARTED | Fentanyl-Midazolam | 12 | |
| Overall Study | COMPLETED | Etomidate | 18 | |
| Overall Study | COMPLETED | Fentanyl-Midazolam | 12 | |
| Overall Study | NOT COMPLETED | Etomidate | 0 | |
| Overall Study | NOT COMPLETED | Fentanyl-Midazolam | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | death | Cardiac disorders | Etomidate | 2 | 18 | 2 |
| serious | death | Cardiac disorders | Fentanyl-Midazolam | 0 | 12 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Etomidate | ||
| Total, all-cause mortality | Fentanyl-Midazolam | ||
| Total, other adverse events | Etomidate | 0 | 18 |
| Total, other adverse events | Fentanyl-Midazolam | 0 | 12 |
| Total, serious adverse events | Etomidate | 2 | 18 |
| Total, serious adverse events | Fentanyl-Midazolam | 0 | 12 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 18784570 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Etomidate vs Fentanyl-Midazolam: Number of Deaths | Trial comparisons |
| Etomidate vs Fentanyl-Midazolam: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00462644
GET https://conductscience.org/api/trials/v1/NCT00462644/registered